2 products found
NovaDigm Therapeutics, Inc. Products
-
NovaDigm - Development Vaccine Programs
NovaDigm's lead development candidate, NDV-31, is the first vaccine to provide preclinical "cross-kingdom" protection against both fungal and bacterial pathogens. In preclinical studies, the vaccine demonstrated protection against both vaginal and bloodstream infections due to the fungal pathogen Candida.2 NDV-3 also was protective in preclinical models ...
-
NovaDigm - Model NDV-3A - Recurrent Vulvovaginal Candidiasis (RVVC)
Vulvovaginal candidiasis (VVC), also called vaginal yeast infections, is a condition that affects approximately 75% of the female population between puberty and menopause. Approximately five million women in the U.S. suffer from recurrent vulvovaginal candidiasis (RVVC), which is defined as four or more episodes of VVC in a year. An additional two million women in the U.S. have reported having three VVC episodes a year and may also be candidates for a ...